About Vernalis
Vernalis is a company based in Wokingham (United Kingdom) founded in 1999 was acquired by HitGen in October 2020. It operates as a Professional Services. The company has 85 employees as of December 31, 2021. Vernalis has completed 4 acquisitions, including Cita NeuroPharmaceuticals, Ionix Pharmaceuticals and Pintex. Vernalis offers products and services including Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science. Vernalis operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others.
- Headquarter Wokingham, United Kingdom
- Employees 85 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vernalis (R&D) Limited
-
Annual Revenue
$12.23 K (USD)-39as on Dec 31, 2020
-
Net Profit
-$3.45 K (USD)58as on Dec 31, 2020
-
EBITDA
Not available
-
Latest Funding Round
$57.82 M (USD), Post-IPO
Apr 26, 2016
-
Investors
HitGen
& 5 more
-
Employee Count
85
as on Dec 31, 2021
-
Investments & Acquisitions
Cita NeuroPharmaceuticals
& 3 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vernalis
Vernalis offers a comprehensive portfolio of products and services, including Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science.
Fragment-based methods are used for drug discovery programs.
DNA Encoded Library technology supports innovative drug discovery.
Protein expression and purification services are provided expertly.
People of Vernalis
Unlock access to complete
Funding Insights of Vernalis
Investors in Vernalis
Vernalis has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include HitGen, Ligand Pharmaceuticals and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment portfolios are managed for clients by the firm.
|
Locked | Locked | Locked | |
|
Fund based investment management firm and fund of funds focused on multiple sectors
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Vernalis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vernalis
Vernalis has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cita NeuroPharmaceuticals, Ionix Pharmaceuticals and Pintex.
Investment portfolio details for Vernalis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Analgesic medicines for acute and chronic pain are developed.
|
Locked | Locked | 2001 | Locked | |
|
Small molecule neuropharmaceuticals are developed and commercialized for neurological disorders.
|
Locked | Locked | 1997 | Locked | |
|
Small molecule therapeutics against cancer and infectious diseases
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Vernalis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Vernalis
Detailed financials for Vernalis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vernalis Comparisons
Peer comparison for Vernalis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vernalis
Vernalis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
Detailed competitors of Vernalis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vernalis
Complete news archive for Vernalis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vernalis
Vernalis was founded in 1999 and raised its 1st funding round 6 years after it was founded.
Vernalis is headquartered in Wokingham, United Kingdom. It is registered at Wokingham, Berkshire, United Kingdom.
As of Dec 31, 2021, the latest employee count at Vernalis is 85.
Annual revenue of Vernalis is $12.23K as on Dec 31, 2020.
Vernalis is involved in enabling drug discovery programs through structure-based and fragment-based approaches. Expertise is applied in protein science, hit identification, and lead optimization across therapeutic areas like oncology and inflammatory diseases. Collaborations are established with various organizations to tackle challenging targets. Services are provided in-house at fully equipped laboratories in Cambridge, UK, covering biophysics, chemistry, and cell biology. Solutions are tailored for both short-term and long-term projects to deliver pre-clinical candidates.
Vernalis's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Vernalis offers Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science.
Vernalis has made 4 acquisitions, including Cita NeuroPharmaceuticals, Ionix Pharmaceuticals, and Pintex.
Vernalis has 6 investors. Key investors include HitGen, Ligand Pharmaceuticals, European Union, Invesco Mutual Fund, and Woodford Investment Management.